表 1. Comparison of clinical data and laboratory indices among the four groups.
四组临床资料及实验室指标比较
| Item | Type | UAP group (n = 69) |
STEMI group (n = 101) |
NSTEMI group (n = 46) |
Control group (n = 94) |
χ2/F | P |
| UAP: unstable angina pectoris; STEMI: ST elevation myocardial infarction; NSTEMI: non-ST elevation myocardial infarction; BMI: body mass index; PCI: percutaneous coronary intervention; MYO: myoglobin; cTnI: cardiac troponin I; NT-proBNP: N-terminal pro-brain natriuretic peptide; CHO: cholesterol; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglyceride; CK-MB: creatine kinase-MB; hs-CRP: hypersensitive C-reactive protein; MPO: myeloperoxidase; MACE: major adverse cardiovascular event. 1 mmHg=0.133 kPa. * P < 0.05, vs. UAP group; # P < 0.05, vs. STEMI group; △ P < 0.05, vs. NSTEMI group. | |||||||
| Sex/case (%) | Male | 54 (78.26) | 77 (76.24) | 30 (65.22) | 33 (35.11) | 45.726 | < 0.001 |
| Female | 15 (21.74) | 24 (23.76) | 16 (34.78) | 61 (64.89) | |||
| Age/yr. | － | 65.99 ± 8.02 | 60.33 ± 11.43* | 68.20 ± 9.22# | 60.73 ± 10.28*, △ | 10.029 | < 0.001 |
| BMI/(kg/m2) | － | 24.71 ± 3.40 | 25.17 ± 3.50 | 24.78 ± 3.58 | 25.25 ± 3.82 | 0.438 | 0.726 |
| Systolic blood pressure/mmHg | － | 137.64 ± 12.20 | 130.55 ± 21.46* | 134.07 ± 24.50*, # | 135.94 ± 15.17*, # | 2.379 | 0.070 |
| Diastolic blood pressure/mmHg | － | 86.03 ± 11.70 | 82.18 ± 13.00* | 81.98 ± 13.63* | 82.73 ± 8.94# | 1.813 | 0.145 |
| Heart rate/min－1 | － | 79.88 ± 13.08 | 81.03 ± 16.31 | 78.78 ± 16.57 | 76.81 ± 13.02 | 1.408 | 0.241 |
| Gensini score | － | 23.87 ± 2.56 | 47.56 ± 5.25* | 55.13 ± 5.91*, # | 0.34 ± 0.08*, #, △ | 3102.651 | < 0.001 |
| Number of vascular lesions/case (%) | 0 | 2 (2.90) | 0 (0) | 0 (0) | 93 (98.94) | 318.014 | < 0.001 |
| 1 | 34 (49.28) | 34 (33.66) | 7 (15.22) | 1 (1.06) | |||
| 2 | 16 (23.19) | 33 (32.67) | 20 (43.48) | 0 (0) | |||
| 3 | 17 (24.63) | 34 (33.67) | 19 (41.30) | 0 (0) | |||
| Smoking history/case (%) | Yes | 32 (46.38) | 44 (43.56) | 24 (52.17) | 29 (30.85) | 7.395 | 0.060 |
| No | 37 (53.62) | 57 (56.44) | 22 (47.83) | 65 (69.15) | |||
| Drinking history/case (%) | Yes | 23 (33.33) | 32 (31.68) | 15 (32.61) | 17 (18.09) | 6.711 | 0.082 |
| No | 46 (66.67) | 69 (68.32) | 31 (67.39) | 77 (81.91) | |||
| Hypertension/case (%) | Yes | 45 (65.22) | 52 (51.49) | 28 (60.87) | 43 (45.74) | 7.205 | 0.066 |
| No | 24 (34.78) | 49 (48.51) | 18 (39.13) | 51 (54.26) | |||
| Diabetes/case (%) | Yes | 21 (30.43) | 34 (33.66) | 12 (26.09) | 12 (12.77) | 12.464 | < 0.001 |
| No | 48 (69.57) | 67 (66.34) | 34 (73.91) | 82 (87.23) | |||
| Abnormal glucose metabolism/case (%) | Yes | 22 (31.88) | 35 (34.65) | 12 (26.09) | 13 (13.83) | 12.240 | < 0.001 |
| No | 47 (68.12) | 66 (65.35) | 34 (73.91) | 81 (86.17) | |||
| Lipid abnormalities/case (%) | Yes | 33 (47.83) | 54 (53.47) | 27 (58.70) | 43 (45.74) | 2.637 | 0.451 |
| No | 36 (52.17) | 47 (46.53) | 19 (41.30) | 51 (54.26) | |||
| History of myocardial infarction/case (%) | Yes | 9 (13.04) | 7 (6.93) | 9 (19.57) | 1 (1.06) | 16.267 | < 0.001 |
| No | 60 (86.96) | 94 (93.07) | 37 (80.43) | 93 (98.94) | |||
| History of PCI/case (%) | Yes | 17 (24.64) | 10 (9.90) | 9 (19.57) | 2 (2.13) | 21.606 | < 0.001 |
| No | 52 (75.36) | 91 (90.10) | 37 (80.43) | 92 (97.87) | |||
| Previous history of cerebrovascular disease/case (%) |
Yes | 6 (8.70) | 7 (6.93) | 9 (19.57) | 6 (6.38) | 7.567 | 0.056 |
| No | 63 (91.30) | 94 (93.07) | 37 (80.43) | 88 (93.62) | |||
| Laboratory indices | |||||||
| MYO/(ng/mL) | － | 26.47 ± 2.95 | 307.45 ± 52.36* | 130.64 ± 14.72*, # | 26.55 ± 2.78#, △ | 1760.254 | < 0.001 |
| cTnI/(pg/mL) | － | 0.020 ± 0.010 | 14.12 ± 2.24* | 13.68 ± 1.70* | 0.007 ± 0.002#, △ | 2436.180 | < 0.001 |
| NT-proBNP/(pg/mL) | － | 93.96 ± 23.81 | 949.41 ± 152.56* | 1914.18 ± 218.30*, # | 72.16 ± 7.31#, △ | 3054.724 | < 0.001 |
| White blood cell count/(×109 L－1) | － | 6.97 ± 2.01 | 10.36 ± 3.23* | 8.80 ± 4.32*, # | 5.83 ± 1.50*, #, △ | 47.987 | < 0.001 |
| Uric acid/(μmol/L) | － | 320.80 ± 101.77 | 317.51 ± 87.72 | 362.91 ± 198.64 | 309.24 ± 90.61 | 2.398 | 0.068 |
| Creatinine/(μmol/L) | － | 72.28 ± 9.58 | 71.77 ± 8.10 | 79.91 ± 8.81*, # | 61.56 ± 6.79*, #, △ | 58.917 | < 0.001 |
| CHO/(mmol/L) | － | 4.01 ± 1.09 | 4.70 ± 1.30* | 4.47 ± 1.31 | 4.41 ± 1.04* | 4.747 | 0.003 |
| HDL-C/(mmol/L) | － | 1.04 ± 0.25 | 1.05 ± 0.33 | 0.92 ± 0.32 | 1.14 ± 0.29*, △ | 5.986 | < 0.001 |
| LDL-C/(mmol/L) | － | 2.34 ± 0.80 | 2.96 ± 1.01* | 3.04 ± 1.38 | 2.60 ± 0.84# | 7.539 | < 0.001 |
| TG/(mmol/L) | － | 1.79 ± 1.01 | 1.95 ± 0.22 | 1.75 ± 0.87 | 1.85 ± 0.21 | 0.267 | 0.849 |
| CK-MB/(IU/L) | － | 2.35 ± 0.49 | 42.84 ± 5.52* | 35.16 ± 3.69*, # | 2.44 ± 0.33#, △ | 3145.627 | < 0.001 |
| hs-CRP/(mg/L) | － | 12.59 ± 1.37 | 19.56 ± 2.60* | 12.70 ± 1.58# | 1.45 ± 0.17*, #, △ | 1799.136 | < 0.001 |
| MPO/(ng/mL) | － | 100.43 ± 12.38 | 163.56 ± 16.76* | 175.90 ± 14.59*, # | 83.94 ± 9.17#, △ | 853.760 | < 0.001 |
| Incidence of MACE/case (%) | 0 (0) | 3 (2.97) | 7 (15.22) | 0 (0) | 26.644 | < 0.001 | |